title: [Regional Differences in the Care of Patients with Neovascular Age-Related Macular Degeneration, Based on the Non-Interventional OCEAN Study].
abstract: Background:The main cause of blindness in the elderly in Germany is neovascular age-related macular degeneration (nAMD). In the non-interventional OCEAN study, data were prospectively collected on the routine clinical care of patients treated with the drug ranibizumab.Patients:As part of an interim analysis within the ongoing study (NCT02194803), stratification was performed by the 17 regions of the German associations of panel physicians and by areas of different population density. Only data were analysed for patients for whom the first treatment with ranibizumab was documented.Results:A total of 5,606 patients were documented. The present manuscript reviews 2,658 treatment-naive patients with nAMD, documented by 324 ophthalmologists. Most patients receiving an intravitreal injection were female (60 %). The average patient was aged 77.7 ± 8.2 years at study start. The great majority of patients had statutory health insurance (91 %). At baseline, fluorescein angiography (FLA) was performed for 72 % of patients, while optical coherence tomography (OCT) was carried out for 76 %. A combination of both was performed for 54 % of patients, varying regionally from 26 % (Saxony-Anhalt) to 100 % (Berlin). The average waiting time between the first examination and the first injection was 20.0 ± 18.5 days. With different statistical models (ANOVA adjusted, with/without interactions), significant effects on treatment delay were found for district type (population density), federal state and type of specialist.Conclusion:No major regional differences were observed in the demographic characteristics of the patient population. The main regional disparities in the care of nAMD patients were in the application of diagnostic methods and the waiting times between the first examination and the first drug administration. The regional variations in treatment delays could clearly influence the risk of worse functional outcome.
authors.affiliation: Department für Augenheilkunde, Eberhard-Karls-Universität Tübingen.
authors.forename: F
authors.initials: F
authors.lastname: Ziemssen
authors.affiliation: Augenarztpraxis, Werningerode.
authors.forename: U
authors.initials: U
authors.lastname: Hufenbach
authors.affiliation: Medical Advisor, Novartis Pharma, Nürnberg.
authors.forename: A
authors.initials: A
authors.lastname: Wiedon
authors.affiliation: Augenarztpraxis, Rhauderfehn.
authors.forename: M
authors.initials: M
authors.lastname: Scheffler
authors.affiliation: Universitätsaugenklinik, Philipps-Universität Marburg.
authors.forename: T
authors.initials: T
authors.lastname: Bertelmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D005260:Female; D005858:Germany / Q000453:epidemiology; D006297:Health Services Accessibility / Q000706:statistics & numerical data*; D054625:Healthcare Disparities / Q000706:statistics & numerical data*; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D015995:Prevalence; D000069579:Ranibizumab / Q000008:administration & dosage; D012189:Retrospective Studies; D012307:Risk Factors; D012424:Rural Population / Q000706:statistics & numerical data*; D061665:Time-to-Treatment; D016896:Treatment Outcome; D057135:Wet Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology*
chemical_list: D020533:Angiogenesis Inhibitors; D000069579:Ranibizumab